Solu-Cortef
NK T-Cell Lymphoma
National Cancer Institute (NCI)Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the NK T-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
tr115 Tarapeutics Science Inc. | Phase 3 | B |
CHLORAMBUCIL Tarapeutics Science Inc. | Phase 3 | B |
(+)-VINCRISTINE Peking University | Phase 2 | B |
Cladribine Tarapeutics Science Inc. | Phase 3 | B |
PREDNISONE TABLETS Peking University | Phase 2 | B |
rd13-02 cell infusion Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 | CC |
Siplizumab National Cancer Institute (NCI) | Phase 1 | C |
Same molecule, other indications
Solu-Cortef is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →